Icon	Function
💬	A pop-up explanation appears when you mouse-over the text beside this icon. Also, an explanation window appears when you click this icon.
	The links beside this icon are links to external sites.
	Clicking this icon sorts the table by the item with this icon (Numerical or alphabetical order). Each click toggles between ascending and descending order.
	A text longer than 100 characters is fully displayed or collapsed.
	The contents of the displayed table are downloaded as a file named "table.csv".

131. Alexander disease Disease details / Clinical trials / Drug dev / DR info /

Clinical trials : 4 / Drugs : 4 - (DrugBank : 1) / Drug target gene : 0 - Drug target pathway : 0

Drugs, Primary sponsors and Trial info (Enrollment year, Phase, Trial ID, Countries)

2'-O-(2-methoxyethyl)-D-ribose antisense oligonucleotide targeting
   IONIS PHARMACEUTICALS, INC.
      2021   Phase 1;Phase 2;Phase 3   EUCTR2020-000976-40-IT   Argentina;Australia;Canada;Israel;Italy;Japan;Netherlands;United Kingdom;United States
2'-O-(2-methoxyethyl)-D-ribose antisense oligonucleotide targeting glial fibrillary acidic protein messenger ribonucleic acid
   Ionis Pharmaceuticals
      2021   Phase 1;Phase 2;Phase 3   EUCTR2020-000976-40-NL   Canada;Israel;Italy;Japan;Netherlands;United Kingdom;United States
   Ionis Pharmaceuticals, Inc
      -   Phase 1;Phase 2;Phase 3   EUCTR2020-000976-40-GB   Argentina;Australia;Canada;Israel;Italy;Japan;Netherlands;United Kingdom;United States
ION373
   IONIS PHARMACEUTICALS, INC.
      2021   Phase 1;Phase 2;Phase 3   EUCTR2020-000976-40-IT   Argentina;Australia;Canada;Israel;Italy;Japan;Netherlands;United Kingdom;United States
   Ionis Pharmaceuticals
      2021   Phase 1;Phase 2;Phase 3   EUCTR2020-000976-40-NL   Canada;Israel;Italy;Japan;Netherlands;United Kingdom;United States
   Ionis Pharmaceuticals, Inc
      -   Phase 1;Phase 2;Phase 3   EUCTR2020-000976-40-GB   Argentina;Australia;Canada;Israel;Italy;Japan;Netherlands;United Kingdom;United States
Zilganersen
   Ionis Pharmaceuticals, Inc.
      2021   Phase 3   NCT04849741   Australia;Canada;Israel;Italy;Japan;Netherlands;United Kingdom;United States